Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 32

1.

The Effect of Dolutegravir on the Pharmacokinetics of Metformin in Healthy Subjects.

Song IH, Zong J, Borland J, Jerva F, Wynne B, Zamek-Gliszczynski MJ, Humphreys JE, Bowers GD, Choukour M.

J Acquir Immune Defic Syndr. 2016 Aug 1;72(4):400-7. doi: 10.1097/QAI.0000000000000983.

2.

Drug interaction profile of the HIV integrase inhibitor cabotegravir: assessment from in vitro studies and a clinical investigation with midazolam.

Reese MJ, Bowers GD, Humphreys JE, Gould EP, Ford SL, Webster LO, Polli JW.

Xenobiotica. 2016;46(5):445-56. doi: 10.3109/00498254.2015.1081993. Epub 2015 Sep 4.

PMID:
26340566
3.

In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor.

Reese MJ, Savina PM, Generaux GT, Tracey H, Humphreys JE, Kanaoka E, Webster LO, Harmon KA, Clarke JD, Polli JW.

Drug Metab Dispos. 2013 Feb;41(2):353-61. doi: 10.1124/dmd.112.048918. Epub 2012 Nov 6.

PMID:
23132334
4.

Assessment of the drug interaction risk for remogliflozin etabonate, a sodium-dependent glucose cotransporter-2 inhibitor: evidence from in vitro, human mass balance, and ketoconazole interaction studies.

Sigafoos JF, Bowers GD, Castellino S, Culp AG, Wagner DS, Reese MJ, Humphreys JE, Hussey EK, O'Connor Semmes RL, Kapur A, Tao W, Dobbins RL, Polli JW.

Drug Metab Dispos. 2012 Nov;40(11):2090-101. doi: 10.1124/dmd.112.047258. Epub 2012 Jul 30.

PMID:
22851617
5.

Oral sulfasalazine as a clinical BCRP probe substrate: pharmacokinetic effects of genetic variation (C421A) and pantoprazole coadministration.

Adkison KK, Vaidya SS, Lee DY, Koo SH, Li L, Mehta AA, Gross AS, Polli JW, Humphreys JE, Lou Y, Lee EJ.

J Pharm Sci. 2010 Feb;99(2):1046-62. doi: 10.1002/jps.21860.

PMID:
19569219
6.

Biopharmaceutics classification system: validation and learnings of an in vitro permeability assay.

Thiel-Demby VE, Humphreys JE, St John Williams LA, Ellens HM, Shah N, Ayrton AD, Polli JW.

Mol Pharm. 2009 Jan-Feb;6(1):11-8. doi: 10.1021/mp800122b.

PMID:
19248229
7.

The role of efflux and uptake transporters in [N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine (GW572016, lapatinib) disposition and drug interactions.

Polli JW, Humphreys JE, Harmon KA, Castellino S, O'Mara MJ, Olson KL, John-Williams LS, Koch KM, Serabjit-Singh CJ.

Drug Metab Dispos. 2008 Apr;36(4):695-701. doi: 10.1124/dmd.107.018374. Epub 2008 Jan 23.

PMID:
18216274
8.

Differential involvement of Mrp2 (Abcc2) and Bcrp (Abcg2) in biliary excretion of 4-methylumbelliferyl glucuronide and sulfate in the rat.

Zamek-Gliszczynski MJ, Hoffmaster KA, Humphreys JE, Tian X, Nezasa K, Brouwer KL.

J Pharmacol Exp Ther. 2006 Oct;319(1):459-67. Epub 2006 Jul 20.

PMID:
16857726
9.

In vitro p-glycoprotein inhibition assays for assessment of clinical drug interaction potential of new drug candidates: a recommendation for probe substrates.

Rautio J, Humphreys JE, Webster LO, Balakrishnan A, Keogh JP, Kunta JR, Serabjit-Singh CJ, Polli JW.

Drug Metab Dispos. 2006 May;34(5):786-92. Epub 2006 Feb 2.

PMID:
16455806
10.

Multiple mechanisms are involved in the biliary excretion of acetaminophen sulfate in the rat: role of Mrp2 and Bcrp1.

Zamek-Gliszczynski MJ, Hoffmaster KA, Tian X, Zhao R, Polli JW, Humphreys JE, Webster LO, Bridges AS, Kalvass JC, Brouwer KL.

Drug Metab Dispos. 2005 Aug;33(8):1158-65. Epub 2005 Apr 28.

PMID:
15860656
11.
12.

The systemic exposure of an N-methyl-D-aspartate receptor antagonist is limited in mice by the P-glycoprotein and breast cancer resistance protein efflux transporters.

Polli JW, Baughman TM, Humphreys JE, Jordan KH, Mote AL, Webster LO, Barnaby RJ, Vitulli G, Bertolotti L, Read KD, Serabjit-Singh CJ.

Drug Metab Dispos. 2004 Jul;32(7):722-6.

PMID:
15205387
13.

A phase II study of G17DT in gastric carcinoma.

Gilliam AD, Watson SA, Henwood M, McKenzie AJ, Humphreys JE, Elder J, Iftikhar SY, Welch N, Fielding J, Broome P, Michaeli D.

Eur J Surg Oncol. 2004 Jun;30(5):536-43.

PMID:
15135483
14.

Predicting P-glycoprotein substrates by a quantitative structure-activity relationship model.

Gombar VK, Polli JW, Humphreys JE, Wring SA, Serabjit-Singh CS.

J Pharm Sci. 2004 Apr;93(4):957-68.

PMID:
14999732
15.

A vaccination strategy for the long-term suppression of androgens in advanced prostate cancer.

Parkinson RJ, Simms MS, Broome P, Humphreys JE, Bishop MC.

Eur Urol. 2004 Feb;45(2):171-4; discussion 174-5.

PMID:
14734002
16.

P-glycoprotein influences the brain concentrations of cetirizine (Zyrtec), a second-generation non-sedating antihistamine.

Polli JW, Baughman TM, Humphreys JE, Jordan KH, Mote AL, Salisbury JA, Tippin TK, Serabjit-Singh CJ.

J Pharm Sci. 2003 Oct;92(10):2082-9.

PMID:
14502547
17.

Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs.

Mahar Doan KM, Humphreys JE, Webster LO, Wring SA, Shampine LJ, Serabjit-Singh CJ, Adkison KK, Polli JW.

J Pharmacol Exp Ther. 2002 Dec;303(3):1029-37.

PMID:
12438524
18.

Rational use of in vitro P-glycoprotein assays in drug discovery.

Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, Serabjit-Singh CS.

J Pharmacol Exp Ther. 2001 Nov;299(2):620-8.

PMID:
11602674
19.

Influence of passive permeability on apparent P-glycoprotein kinetics.

Lentz KA, Polli JW, Wring SA, Humphreys JE, Polli JE.

Pharm Res. 2000 Dec;17(12):1456-60.

PMID:
11303953
20.

Anti-GnRH antibodies can induce castrate levels of testosterone in patients with advanced prostate cancer.

Simms MS, Scholfield DP, Jacobs E, Michaeli D, Broome P, Humphreys JE, Bishop MC.

Br J Cancer. 2000 Aug;83(4):443-6.

21.

P-glycoprotein-mediated transport of morphine in brain capillary endothelial cells.

Letrent SP, Polli JW, Humphreys JE, Pollack GM, Brouwer KR, Brouwer KL.

Biochem Pharmacol. 1999 Sep 15;58(6):951-7.

PMID:
10509747
22.

Role of P-glycoprotein on the CNS disposition of amprenavir (141W94), an HIV protease inhibitor.

Polli JW, Jarrett JL, Studenberg SD, Humphreys JE, Dennis SW, Brouwer KR, Woolley JL.

Pharm Res. 1999 Aug;16(8):1206-12.

PMID:
10468021
23.

A clarithromycin sensitivity survey in the United Kingdom using Stokes' method.

Humphreys JE, Smith EG, Coles SJ.

J Antimicrob Chemother. 1993 Aug;32(2):341-2. No abstract available.

PMID:
8226438
24.

Comparison of antihypertensive and lipid actions of terazosin and atenolol in essential hypertension.

Silke B, Guy S, Humphreys JE.

J Hum Hypertens. 1992 Jun;6(3):221-5.

PMID:
1352828
25.

A relative cost-effectiveness analysis of different methods of screening for diabetic retinopathy.

Sculpher MJ, Buxton MJ, Ferguson BA, Humphreys JE, Altman JF, Spiegelhalter DJ, Kirby AJ, Jacob JS, Bacon H, Dudbridge SB, et al.

Diabet Med. 1991 Aug-Sep;8(7):644-50.

PMID:
1833116
26.

Screening for treatable diabetic retinopathy: a comparison of different methods.

Buxton MJ, Sculpher MJ, Ferguson BA, Humphreys JE, Altman JF, Spiegelhalter DJ, Kirby AJ, Jacob JS, Bacon H, Dudbridge SB, et al.

Diabet Med. 1991 May;8(4):371-7.

PMID:
1830260
27.

Comparison of cadmium cytotoxicity in human versus rat nasal epithelial cells in vitro.

Morgan DL, Humphreys JE, Bilotta JM, Nixon JC, Hatch GE, Steele VE.

Toxicol In Vitro. 1990;4(2):123-7.

PMID:
20702272
28.
29.

Alpha-1 blockers. A new generation of antihypertensive agents.

Humphreys JE, Waite MA.

J Clin Pharm Ther. 1989 Aug;14(4):263-83. Review.

PMID:
2571616
30.

Pharmacokinetics of single and multiple doses of flusoxolol (Ro 31-1411) in healthy subjects.

Gillies HC, Rogers HJ, Francis RJ, Galloway DB, Humphreys JE.

Eur J Clin Pharmacol. 1986;31(1):113-5.

PMID:
2877883
32.

BOTANY IN JAMAJCA.

Humphreys JE.

Science. 1893 Aug 18;22(550):85. No abstract available.

PMID:
17819058

Supplemental Content

Loading ...
Support Center